GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Status:
Completed
Trial end date:
2017-07-21
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the overall survival (OS) of subjects with
previously treated metastatic pancreatic cancer treated with cyclophosphamide
(CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects
treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Aduro BioTech Aduro Biotech, Inc. American Association for Cancer Research Bristol-Myers Squibb Lustgarten Foundation Stand Up To Cancer